Company’s 36-month beta value is 0.25.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for KTTA is 6.84M, and currently, short sellers hold a 2.79% ratio of that floaft. The average trading volume of KTTA on July 04, 2025 was 6.28M shares.
KTTA stock’s latest price update
Pasithea Therapeutics Corp (NASDAQ: KTTA) has seen a decline in its stock price by -2.09% in relation to its previous close of $0.75. However, the company has experienced a -0.25% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-11 that MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indications, and also identified that MEK inhibitors are the drug class that most effectively suppress ETS2-driven inflammation.
KTTA’s Market Performance
KTTA’s stock has fallen by -0.25% in the past week, with a monthly drop of -20.41% and a quarterly drop of -38.47%. The volatility ratio for the week is 5.63% while the volatility levels for the last 30 days are 5.90% for Pasithea Therapeutics Corp The simple moving average for the last 20 days is -6.79% for KTTA stock, with a simple moving average of -67.87% for the last 200 days.
KTTA Trading at -27.14% from the 50-Day Moving Average
After a stumble in the market that brought KTTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.24% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 5.63%, as shares sank -19.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.45% lower at present.
During the last 5 trading sessions, KTTA fell by -0.25%, which changed the moving average for the period of 200-days by -81.08% in comparison to the 20-day moving average, which settled at $0.7855. In addition, Pasithea Therapeutics Corp saw -86.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Marques Tiago, the Chief Executive Officer of Pasithea Therapeutics Corp, sale 960 shares at $0.82 during a trade that took place back on May 12 ’25, which means that Marques Tiago is holding 40,001 shares at $792 based on the most recent closing price.
Stock Fundamentals for KTTA
The total capital return value is set at -0.0%. Equity return is now at value -82.81%, with -73.42% for asset returns.
Currently, EBITDA for the company is -13.26 million with net debt to EBITDA at 406.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.84.
Conclusion
In a nutshell, Pasithea Therapeutics Corp (KTTA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
